NeuroSense Therapeutics reported encouraging results from a biomarker study evaluating CogniC, its combination therapy for Alzheimer’s disease (AD). The study identified key AD-related biomarkers, including miRNA dysregulation, lysosomal dysfunction, impaired autophagy, and elevated levels of amyloid-β, tau, and TDP-43 proteins, suggesting CogniC may target multiple disease pathways.
Notably, TDP-43, a protein increasingly recognized as central to AD pathology, was found at significantly higher levels in AD patients. NeuroSense has previously demonstrated the ability to impact TDP-43 in a Phase IIa ALS study, supporting its broader therapeutic potential.
The study leveraged neuron-derived exosome (NDE) technology to non-invasively analyze central nervous system biomarkers from blood samples. A clinical proof-of-concept study with a leading AD clinic is planned for 2023, with additional findings to be presented at scientific conferences and in peer-reviewed publications.
